Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

Vitrolife

Vitrolife

Read in Swedish

Vitrolife AB (publ): Report on Operations 2020: Strong end to a turbulent year

08:00 / 10 February 2021 Vitrolife Press release

Fourth quarter
  • Sales amounted to SEK 382 (409) million, corresponding to a decrease of 7 percent in SEK. Sales were unchanged in local currency.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 164 (160) million, corresponding to a margin of 43 (39) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 21 million.
  • Net income amounted to SEK 108 (96) million, which gave earnings per share of SEK 0.99 (0.89).
Whole year 2020
  • Sales amounted to SEK 1 246 (1 480) million, corresponding to a decrease of 16 percent in SEK. Sales decreased by 13 percent in local currency.
  • Operating income before depreciation and amortisation (EBITDA) amounted to SEK 454 (587) million, corresponding to a margin of 36 (40) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 24 million.
  • Net income amounted to SEK 288 (384) million, which gave earnings per share of SEK 2.64 (3.53).
After the end of the period
  • The Board proposes a dividend of SEK 87 (-) million, corresponding to SEK 0.80 (-) per share.
  • Lawsuit received regarding claimed patent infringement with regard to Time-lapse in Germany.

Gothenburg, February 10, 2021
VITROLIFE AB (publ)
Thomas Axelsson, CEO

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com.Website: www.vitrolife.com/

Show as PDF

Show original from Cision

Cision

This information was distributed by Cision http://www.cisionwire.se/